(12) - Thrombophilias Prospective Detection Tailored Anticoagulation Protocol Without Antiplatelet Therapy in Patients With Axial-Flow Ventricular Assist Device

Abstract

s S13 in VKORC1 gene which increases sebsitivity to Warfarin had significantly higher risk of device thrombosis compared to patients with wild-type only alleles (27.0% vs. 7.7% at 1 year, respectively, OR 4.76, p= 0.030, Figure). Post-LVAD survival was not different between different genotype groups. Conclusion: Our findings suggest an association between rare VKORC1 variants that increase sensitivity to Warfarin, increased INR variability, and risk of device thrombosis. Genotype specific warfarin dosing algorithms to reduce INR variability should be explored.